Hendrik Andreas Wolff
Research Subjects
Hendrik Andreas Wolff has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Hille
Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany
2 shared publications Christoph Matthias
Department of Otorhinolaryngology; Head and Neck Surgery; University of Göttingen; Germany
2 shared publicationsClemens F. Hess
University Medical Center Göttingen
2 shared publications- Clemens Friedrich Hess
Klinik und Poliklinik für Strahlentherapie und Radioonkologie der Georg-August-Universität Göttingen
2 shared publications - Hans Christiansen
Department of Radiotherapy, University of Goettingen, Goettingen, Germany
2 shared publications - Jochen Gaedcke
Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany
2 shared publications
Latest Publications
- Open Access
- 27 May 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (6) , 1140
Changes of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy
Since the response to chemoradiotherapy in patients with locally advanced rectal cancer is heterogeneous, valid biomarkers are needed to monitor tumor response. Circulating microRNAs are promising candidates, however analyses of circulating microRNAs in rectal cancer are still rare. 111 patients with rectal cancer and 46 age-matched normal controls were enrolled. The expression levels of 30 microRNAs were analyzed in 17 pre-treatment patients’ plasma samples. Differentially regulated microRNAs were validated in 94 independent patients. For 52 of the 94 patients a paired comparison between pre-treatment and post-treatment samples was performed. miR-17, miR-18b, miR-20a, miR-31, and miR-193a_3p, were significantly downregulated in pre-treatment plasma samples of patients with rectal cancer (p < 0.05). miR-29c, miR-30c, and miR-195 showed a trend of differential regulation. After validation, miR-31 and miR-30c were significantly deregulated by a decrease of expression. In 52 patients expression analyses of the 8 microRNAs in matched pre-treatment and post-treatment samples showed a significant decrease for all microRNAs (p < 0.05) after treatment. Expression levels of miR-31 and miR-30c could serve as valid biomarkers if validated in a prospective study. Plasma microRNA expression levels do not necessarily represent miRNA expression levels in tumor tissue. Also, expression levels of microRNAs change during multimodal therapy.
- 27 May 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (6) , 1140
Open AccessChanges of Microrna Levels in Plasma of Patients with Rectal Cancer during Chemoradiotherapy
Since the response to chemoradiotherapy in patients with locally advanced rectal cancer is heterogeneous, valid biomarkers are needed to monitor tumor response. Circulating microRNAs are promising candidates, however analyses of circulating microRNAs in rectal cancer are still rare. 111 patients with rectal cancer and 46 age-matched normal controls were enrolled. The expression levels of 30 microRNAs were analyzed in 17 pre-treatment patients’ plasma samples. Differentially regulated microRNAs were validated in 94 independent patients. For 52 of the 94 patients a paired comparison between pre-treatment and post-treatment samples was performed. miR-17, miR-18b, miR-20a, miR-31, and miR-193a_3p, were significantly downregulated in pre-treatment plasma samples of patients with rectal cancer (p < 0.05). miR-29c, miR-30c, and miR-195 showed a trend of differential regulation. After validation, miR-31 and miR-30c were significantly deregulated by a decrease of expression. In 52 patients expression analyses of the 8 microRNAs in matched pre-treatment and post-treatment samples showed a significant decrease for all microRNAs (p < 0.05) after treatment. Expression levels of miR-31 and miR-30c could serve as valid biomarkers if validated in a prospective study. Plasma microRNA expression levels do not necessarily represent miRNA expression levels in tumor tissue. Also, expression levels of microRNAs change during multimodal therapy.
- Open Access
- 20 October 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-8
Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy
Excellent dosimetric characteristics were demonstrated for volumetric modulated arc therapy (VMAT) in preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). In a single-center retrospective analysis, we tested whether these advantages may translate into significant clinical benefits. We compared VMAT to conventional 3D conformal radiotherapy (3DCRT) in patients, homogeneously treated according to the control arm of the CAO/ARO/AIO-04 trial. CRT consisted of pelvic irradiation with 50.4/1.8Gy by VMAT (n = 81) or 3DCRT (n = 107) and two cycles of 5-fluorouracil. Standardized total mesorectal excision surgery was performed within 4–6 weeks. The tumor regression grading (TRG) was assessed by the Dworak score. Acute and late toxicity were evaluated via the Common Terminology Criteria for Adverse Events and the Late effects of normal tissues scale, respectively. Side effects greater than or equal to grade 3 were considered high-grade. Median follow-up was 18.3 months in the VMAT group and 61.5 months in the 3DCRT group with no differences in TRG between them (p = 0.1727). VMAT treatment substantially reduced high-grade acute and late toxicity, with 5 % versus 20 % (p = 0.0081) and 6 % vs. 22 % (p = 0.0039), respectively. With regard to specific organs, differences were found in skin reaction (p = 0.019) and proctitis (p = 0.0153). VMAT treatment in preoperative CRT for LARC showed the potential to substantially reduce high-grade acute and late toxicity. Importantly, we could demonstrate that VMAT irradiation did not impair short-term oncological results. We conclude, that the reduced toxicity after VMAT irradiation may pave the way for more efficient systemic therapies, and hopefully improved patient survival in the multimodal treatment of LARC.
- 20 October 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 1-8
Open AccessReduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated arc therapy and 3D conformal radiotherapy
Excellent dosimetric characteristics were demonstrated for volumetric modulated arc therapy (VMAT) in preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC). In a single-center retrospective analysis, we tested whether these advantages may translate into significant clinical benefits. We compared VMAT to conventional 3D conformal radiotherapy (3DCRT) in patients, homogeneously treated according to the control arm of the CAO/ARO/AIO-04 trial. CRT consisted of pelvic irradiation with 50.4/1.8Gy by VMAT (n = 81) or 3DCRT (n = 107) and two cycles of 5-fluorouracil. Standardized total mesorectal excision surgery was performed within 4–6 weeks. The tumor regression grading (TRG) was assessed by the Dworak score. Acute and late toxicity were evaluated via the Common Terminology Criteria for Adverse Events and the Late effects of normal tissues scale, respectively. Side effects greater than or equal to grade 3 were considered high-grade. Median follow-up was 18.3 months in the VMAT group and 61.5 months in the 3DCRT group with no differences in TRG between them (p = 0.1727). VMAT treatment substantially reduced high-grade acute and late toxicity, with 5 % versus 20 % (p = 0.0081) and 6 % vs. 22 % (p = 0.0039), respectively. With regard to specific organs, differences were found in skin reaction (p = 0.019) and proctitis (p = 0.0153). VMAT treatment in preoperative CRT for LARC showed the potential to substantially reduce high-grade acute and late toxicity. Importantly, we could demonstrate that VMAT irradiation did not impair short-term oncological results. We conclude, that the reduced toxicity after VMAT irradiation may pave the way for more efficient systemic therapies, and hopefully improved patient survival in the multimodal treatment of LARC.
- 10 January 2015
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 191 (7) , 566-572
High-grade acute organ toxicity and p16INK4A expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma
Superior treatment response and survival for patients with human papilloma virus (HPV)-positive head and neck cancer (HNSCC) are documented in clinical studies. However, the relevance of high-grade acute organ toxicity (HGAOT), which has also been correlated with improved prognosis, has attracted scant attention in HPV-positive HNSCC patients. Hence we tested the hypothesis that both parameters, HPV and HGAOT, are positive prognostic factors in patients with HNSCC treated with definite radiotherapy (RT) or radiochemotherapy (RCT). Pretreatment tumor tissue and clinical records were available from 233 patients receiving definite RT (62 patients) or RCT (171 patients). HPV infection was analysed by means of HPV DNA detection or p16INK4A expression; HGAOT was defined as the occurrence of acute organ toxicity >grade 2 according to the Common Toxicity Criteria. Both variables were correlated with overall survival (OS) using Cox proportional hazards regression. Positivity for HPV DNA (44 samples, 18.9 %) and p16INK4A expression (102 samples, 43.8 %) were significantly correlated (p < 0.01), and HGAOT occurred in 77 (33 %) patients. Overall, the 5-year OS was 23 %; stratified for p16INK4A expression and HGAOT, OS rates were 47 %, 42 %, 20 % and 10 % for patients with p16INK4A expression and HGAOT, patients with HGAOT only, patients with p16INK4A expression only, and patients without p16INK4A expression or HGAOT, respectively. After multivariate testing p16INK4A expression (p = 0.003) and HGAOT (p < 0.001) were significantly associated with OS. P16INK4A expression and HGAOT are independent prognostic factors for OS of patients with HNSCC, whereas p16INK4A expression is particularly important for patients without HGAOT. Ein besseres Therapieansprechen von humanen Papillomavirus (HPV)-positiven Kopf-Hals-Tumoren (HNSCC) ist durch Studien belegt. Weniger Beachtung hat bisher die Relevanz unerwünschter Therapienebenwirkungen bei diesem Kollektiv gefunden. Für andere Patientenkollektive ist die Korrelation einer höhergradigen akuten Organtoxizität (HGAOT) mit einem längeren Gesamtüberleben (OS) beschrieben. Wir prüften die Hypothese, dass HPV und HGAOT positive prognostische Faktoren bei Patienten mit HNSCC nach primärer Strahlentherapie oder Radiochemotherapie sind. Von 233 Patienten, die mit einer primären Radiotherapie (62 Patienten) oder Radiochemotherapie (171 Patienten) behandelt wurden, standen umfassende klinische Daten und Tumormaterial als Paraffinblöcke zur Verfügung. Der HPV-Nachweis wurde immunhistochemisch als p16INK4A-Expression oder mittels PCR/nested PCR für Virus-DNA geführt. HGAOT wurde als das Auftreten einer Mukositis, Hautreaktion, Dysphagie oder Übelkeit > Grad 2 nach Common Toxicity Criteria definiert. Der Zusammenhang beider Variablen mit dem Gesamtüberleben wurde mittels Cox-Regression analysiert. In 102 (43,8 %) Tumorgewebeschnitten wurde p16INK4A nachgewiesen, HPV-DNA wurde in 44 Proben gefunden, wobei sich eine signifikante Korrelation zwischen der p16INK4A- und der HPV-DNA-Expression zeigte (p < 0,001). Insgesamt betrug das 5-Jahres-OS 23 %, bei Stratifizierung nach p16INK4A-Expression und dem Auftreten von HGAOT zeigten sich signifikante Abstufungen bezüglich des OS: HGAOT + p16INK4A 47 % OS, nur HGOAT 42 % OS, nur p16INK4A 20 % OS und kein Merkmal 10 % OS – jeweils nach 5 Jahren. Sowohl die p16INK4A-Expression als auch HGAOT waren signifikant mit dem Gesamtüberleben korreliert. Das Auftreten einer HGAOT ist auch für p16INK4A- bzw. HPV-positive Patienten mit HNSCC ein positiver prognostischer Faktor, wobei akute Organtoxizitäten > Grad 2 mit einem signifikant verlängerten OS korreliert sind.
- 10 January 2015
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 191 (7) , 566-572
High-grade acute organ toxicity and p16INK4A expression as positive prognostic factors in primary radio(chemo)therapy for patients with head and neck squamous cell carcinoma
Superior treatment response and survival for patients with human papilloma virus (HPV)-positive head and neck cancer (HNSCC) are documented in clinical studies. However, the relevance of high-grade acute organ toxicity (HGAOT), which has also been correlated with improved prognosis, has attracted scant attention in HPV-positive HNSCC patients. Hence we tested the hypothesis that both parameters, HPV and HGAOT, are positive prognostic factors in patients with HNSCC treated with definite radiotherapy (RT) or radiochemotherapy (RCT). Pretreatment tumor tissue and clinical records were available from 233 patients receiving definite RT (62 patients) or RCT (171 patients). HPV infection was analysed by means of HPV DNA detection or p16INK4A expression; HGAOT was defined as the occurrence of acute organ toxicity >grade 2 according to the Common Toxicity Criteria. Both variables were correlated with overall survival (OS) using Cox proportional hazards regression. Positivity for HPV DNA (44 samples, 18.9 %) and p16INK4A expression (102 samples, 43.8 %) were significantly correlated (p < 0.01), and HGAOT occurred in 77 (33 %) patients. Overall, the 5-year OS was 23 %; stratified for p16INK4A expression and HGAOT, OS rates were 47 %, 42 %, 20 % and 10 % for patients with p16INK4A expression and HGAOT, patients with HGAOT only, patients with p16INK4A expression only, and patients without p16INK4A expression or HGAOT, respectively. After multivariate testing p16INK4A expression (p = 0.003) and HGAOT (p < 0.001) were significantly associated with OS. P16INK4A expression and HGAOT are independent prognostic factors for OS of patients with HNSCC, whereas p16INK4A expression is particularly important for patients without HGAOT. Ein besseres Therapieansprechen von humanen Papillomavirus (HPV)-positiven Kopf-Hals-Tumoren (HNSCC) ist durch Studien belegt. Weniger Beachtung hat bisher die Relevanz unerwünschter Therapienebenwirkungen bei diesem Kollektiv gefunden. Für andere Patientenkollektive ist die Korrelation einer höhergradigen akuten Organtoxizität (HGAOT) mit einem längeren Gesamtüberleben (OS) beschrieben. Wir prüften die Hypothese, dass HPV und HGAOT positive prognostische Faktoren bei Patienten mit HNSCC nach primärer Strahlentherapie oder Radiochemotherapie sind. Von 233 Patienten, die mit einer primären Radiotherapie (62 Patienten) oder Radiochemotherapie (171 Patienten) behandelt wurden, standen umfassende klinische Daten und Tumormaterial als Paraffinblöcke zur Verfügung. Der HPV-Nachweis wurde immunhistochemisch als p16INK4A-Expression oder mittels PCR/nested PCR für Virus-DNA geführt. HGAOT wurde als das Auftreten einer Mukositis, Hautreaktion, Dysphagie oder Übelkeit > Grad 2 nach Common Toxicity Criteria definiert. Der Zusammenhang beider Variablen mit dem Gesamtüberleben wurde mittels Cox-Regression analysiert. In 102 (43,8 %) Tumorgewebeschnitten wurde p16INK4A nachgewiesen, HPV-DNA wurde in 44 Proben gefunden, wobei sich eine signifikante Korrelation zwischen der p16INK4A- und der HPV-DNA-Expression zeigte (p < 0,001). Insgesamt betrug das 5-Jahres-OS 23 %, bei Stratifizierung nach p16INK4A-Expression und dem Auftreten von HGAOT zeigten sich signifikante Abstufungen bezüglich des OS: HGAOT + p16INK4A 47 % OS, nur HGOAT 42 % OS, nur p16INK4A 20 % OS und kein Merkmal 10 % OS – jeweils nach 5 Jahren. Sowohl die p16INK4A-Expression als auch HGAOT waren signifikant mit dem Gesamtüberleben korreliert. Das Auftreten einer HGAOT ist auch für p16INK4A- bzw. HPV-positive Patienten mit HNSCC ein positiver prognostischer Faktor, wobei akute Organtoxizitäten > Grad 2 mit einem signifikant verlängerten OS korreliert sind.
- 20 January 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (3) , 567
HER2 and HER3 expression in hepatic metastases of colorectal cancer: New targets for specific treatment approaches?
567 Background: Even though treatment options for coloretal cancer liver metastases have improved with the implementation of multimodal strategies and new agents, progression of distant metastases is still limiting the prognosis of affected patients. In this context we investigated the expression of HER2 and HER3 in patients with metastatic colorectal cancer and primary tumors. Methods: In this study 226 consecutive patients with hepatic metastases of colorectal cancer were included. HER2 and HER3 expression were determined in the tissue from resected metastases and—if available—in primary tumors. Immunohistochemical scoring (IHC 0 to IHC 3) and S-ISH-amplification-detection (for HER2) were used to determine the HER2 and HER3 status. Results: A positive HER2 status was found in 8.4% of all hepatic metastases; an overexpression of HER-3 in 74,8% of all cases. There was a high congruence of the expression pattern of HER2 and HER3 between hepatic metastases and available primary tumors (>90%). Conclusions: HER2 amplification and HER3 overexpression is detectable in a significant proportion of hepatic metastases of colorectal cancer. These results suggest that innovative new targeted treatment agents might be possible opportunities for the specific therapy of patients with HER2/HER3 positive metastatic colorectal cancer and should be further assessed within prospective clinical trials.
- 20 January 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (3) , 567
HER2 and HER3 expression in hepatic metastases of colorectal cancer: New targets for specific treatment approaches?
567 Background: Even though treatment options for coloretal cancer liver metastases have improved with the implementation of multimodal strategies and new agents, progression of distant metastases is still limiting the prognosis of affected patients. In this context we investigated the expression of HER2 and HER3 in patients with metastatic colorectal cancer and primary tumors. Methods: In this study 226 consecutive patients with hepatic metastases of colorectal cancer were included. HER2 and HER3 expression were determined in the tissue from resected metastases and—if available—in primary tumors. Immunohistochemical scoring (IHC 0 to IHC 3) and S-ISH-amplification-detection (for HER2) were used to determine the HER2 and HER3 status. Results: A positive HER2 status was found in 8.4% of all hepatic metastases; an overexpression of HER-3 in 74,8% of all cases. There was a high congruence of the expression pattern of HER2 and HER3 between hepatic metastases and available primary tumors (>90%). Conclusions: HER2 amplification and HER3 overexpression is detectable in a significant proportion of hepatic metastases of colorectal cancer. These results suggest that innovative new targeted treatment agents might be possible opportunities for the specific therapy of patients with HER2/HER3 positive metastatic colorectal cancer and should be further assessed within prospective clinical trials.
- 25 April 2013
- Published by Wiley in Head & Neck
- Vol. 36 (6) , 787-794
Enoral laser microsurgery for squamous cell carcinoma of the oral cavity
- 25 April 2013
- Published by Wiley in Head & Neck
- Vol. 36 (6) , 787-794
Enoral laser microsurgery for squamous cell carcinoma of the oral cavity
- Open Access
- 20 February 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 24
Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study
To evaluate gold marker displacement due to needle insertion during HDR-brachytherapy for therapy of prostate cancer. 18 patients entered into this prospective evaluation. Three gold markers were implanted into the prostate during the first HDR-brachytherapy procedure after the irradiation was administered. Three days after marker implantation all patients had a CT-scan for planning purpose of the percutaneous irradiation. Marker localization was defined on the digitally-reconstructed-radiographs (DRR) for daily (VMAT technique) or weekly (IMRT) set-up error correction. Percutaneous therapy started one week after first HDR-brachytherapy. After the second HDR-brachytherapy, two weeks after first HDR-brachtherapy, a cone-beam CT-scan was done to evaluate marker displacement due to needle insertion. In case of marker displacement, the actual positions of the gold markers were adjusted on the DRR. The value of the gold marker displacement due to the second HDR-brachytherapy was analyzed in all patients and for each gold marker by comparison of the marker positions in the prostate after soft tissue registration of the prostate of the CT-scans prior the first and second HDR-brachytherapy. The maximum deviation was 5 mm, 7 mm and 12 mm for the anterior-posterior, lateral and superior-inferior direction. At least one marker in each patient showed a significant displacement and therefore new marker positions were adjusted on the DRRs for the ongoing percutaneous therapy. Needle insertion in the prostate due to HDR-brachytherapy can lead to gold marker displacements. Therefore, it is necessary to verify the actual position of markers after the second HDR-brachytherapy. In case of significant deviations, a new DRR with the adjusted marker positions should be generated for precise positioning during the ongoing percutaneous irradiation.
- 20 February 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 24
Open AccessGold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study
To evaluate gold marker displacement due to needle insertion during HDR-brachytherapy for therapy of prostate cancer. 18 patients entered into this prospective evaluation. Three gold markers were implanted into the prostate during the first HDR-brachytherapy procedure after the irradiation was administered. Three days after marker implantation all patients had a CT-scan for planning purpose of the percutaneous irradiation. Marker localization was defined on the digitally-reconstructed-radiographs (DRR) for daily (VMAT technique) or weekly (IMRT) set-up error correction. Percutaneous therapy started one week after first HDR-brachytherapy. After the second HDR-brachytherapy, two weeks after first HDR-brachtherapy, a cone-beam CT-scan was done to evaluate marker displacement due to needle insertion. In case of marker displacement, the actual positions of the gold markers were adjusted on the DRR. The value of the gold marker displacement due to the second HDR-brachytherapy was analyzed in all patients and for each gold marker by comparison of the marker positions in the prostate after soft tissue registration of the prostate of the CT-scans prior the first and second HDR-brachytherapy. The maximum deviation was 5 mm, 7 mm and 12 mm for the anterior-posterior, lateral and superior-inferior direction. At least one marker in each patient showed a significant displacement and therefore new marker positions were adjusted on the DRRs for the ongoing percutaneous therapy. Needle insertion in the prostate due to HDR-brachytherapy can lead to gold marker displacements. Therefore, it is necessary to verify the actual position of markers after the second HDR-brachytherapy. In case of significant deviations, a new DRR with the adjusted marker positions should be generated for precise positioning during the ongoing percutaneous irradiation.
- 15 July 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (4) , 1214-1219
Fractionated External Beam Radiotherapy as a Suitable Preparative Regimen for Hepatocyte Transplantation After Partial Hepatectomy
- 15 July 2011
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 80 (4) , 1214-1219
Fractionated External Beam Radiotherapy as a Suitable Preparative Regimen for Hepatocyte Transplantation After Partial Hepatectomy
- 1 January 2009
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 44 (8) , 939-946
Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: Results of a prospective study
Objective. Acute proctitis and chronic radiation proctitis are relevant complications of pelvic radiation. The purpose of this study was to investigate two markers of gut inflammation during and after irradiation for prostate cancer to evaluate a correlation between acute and chronic proctitis. Material and methods. Two patient groups were analysed. In group 1, stool samples from 20 patients were collected before therapy, every week during therapy, at the end of therapy, and 13 and 27 months after therapy. Group 2 comprised 47 patients who had undergone irradiation 40 months earlier. Toxicity was determined by common toxicity criteria (CTC) and the LENT soma scale. Calprotectin and lactoferrin values were determined by ELISA. Results. In group 1, acute values for both faecal markers were significantly correlated with chronic proctitis symptoms and all patients with chronic toxicity had acute proctitis symptoms with elevated faecal values. In group 2, where stool samples were solely collected 40 months after irradiation, the Pearson square test showed both a significant correlation between calprotectin and lactoferrin values and toxicity after 40 months. Conclusions. Within a group of 19 patients followed for two years after irradiation for prostate cancer, and 47 patients tested 40 months after irradiation, increased faecal values of calprotectin and lactoferrin were significantly correlated with the occurrence of chronic proctitis. This observation should be confirmed in an expanded study.
- 1 January 2009
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 44 (8) , 939-946
Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: Results of a prospective study
Objective. Acute proctitis and chronic radiation proctitis are relevant complications of pelvic radiation. The purpose of this study was to investigate two markers of gut inflammation during and after irradiation for prostate cancer to evaluate a correlation between acute and chronic proctitis. Material and methods. Two patient groups were analysed. In group 1, stool samples from 20 patients were collected before therapy, every week during therapy, at the end of therapy, and 13 and 27 months after therapy. Group 2 comprised 47 patients who had undergone irradiation 40 months earlier. Toxicity was determined by common toxicity criteria (CTC) and the LENT soma scale. Calprotectin and lactoferrin values were determined by ELISA. Results. In group 1, acute values for both faecal markers were significantly correlated with chronic proctitis symptoms and all patients with chronic toxicity had acute proctitis symptoms with elevated faecal values. In group 2, where stool samples were solely collected 40 months after irradiation, the Pearson square test showed both a significant correlation between calprotectin and lactoferrin values and toxicity after 40 months. Conclusions. Within a group of 19 patients followed for two years after irradiation for prostate cancer, and 47 patients tested 40 months after irradiation, increased faecal values of calprotectin and lactoferrin were significantly correlated with the occurrence of chronic proctitis. This observation should be confirmed in an expanded study.
- Open Access
- 24 December 2008
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 135 (7) , 961-967
Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
To evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer (HNSCC). From October 2003 to October 2006, 50 patients with HNSCC (stage III/IVA/IVB) were treated. In 32 patients, surgery and adjuvant radiotherapy(64 Gy), in 18 patients definitive radiotherapy(70 Gy) was performed. Low-dose-cisplatin was applied concomitantly (6 mg/m2/every radiotherapy-day). Acute toxicity ≥grade 3 was observed in 22 patients (11 patients mucositis/dysphagia, 7 hematologic toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90% of our patients received >80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity ≥grade 3 (xerostomia, subcutaneous fibrosis, or lymphedema) was observed in nine patients. We found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials.
- 24 December 2008
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 135 (7) , 961-967
Open AccessToxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
To evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer (HNSCC). From October 2003 to October 2006, 50 patients with HNSCC (stage III/IVA/IVB) were treated. In 32 patients, surgery and adjuvant radiotherapy(64 Gy), in 18 patients definitive radiotherapy(70 Gy) was performed. Low-dose-cisplatin was applied concomitantly (6 mg/m2/every radiotherapy-day). Acute toxicity ≥grade 3 was observed in 22 patients (11 patients mucositis/dysphagia, 7 hematologic toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90% of our patients received >80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity ≥grade 3 (xerostomia, subcutaneous fibrosis, or lymphedema) was observed in nine patients. We found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials.